Literature DB >> 25674385

Budd-Chiari syndrome and liver transplantation.

Nobuhisa Akamatsu1, Yasuhiko Sugawara1, Norihiro Kokudo1.   

Abstract

Budd-Chiari syndrome involves obstruction of hepatic venous outflow tracts at various levels from small hepatic veins to the inferior vena cava and is the result of thrombosis or its fibrous sequelae. There is a conspicuous difference in its etiology in the West and the East. Myeloproliferative disease predominates in the West and obstruction of the vena cava predominates in the East. The clinical presentation and clinical manifestations are so varied that it should be suspected in any patient with acute or chronic liver dysfunction. It should be treated with step-wise management. First-line therapy should be anticoagulation with medical treatment of the underlying illness, and interventional revascularization and TIPS are indicated in the event of a lack of response to medical therapy. Liver transplantation may be indicated as a rescue treatment or for fulminant cases with promising results. This step-by-step strategy has achieved a 5-year transplant-free survival rate of 70% and a 5-year overall survival rate of 90%. Living donor liver transplantation can also be used for patients with Budd-Chiari syndrome if deceased donor livers are scarce, but it requires a difficult procedure particularly with regard to venous outflow reconstruction.

Entities:  

Keywords:  Budd-Chiari syndrome; deceased donor; liver transplantation; living donor

Year:  2015        PMID: 25674385      PMCID: PMC4322592          DOI: 10.5582/irdr.2014.01031

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  86 in total

Review 1.  Living-donor liver transplantation: 12 years of experience in Asia.

Authors:  Chao-Long Chen; Sheung-Tat Fan; Sung-Gyu Lee; Masatoshi Makuuchi; Koichi Tanaka
Journal:  Transplantation       Date:  2003-02-15       Impact factor: 4.939

2.  Live donor liver transplantation for Budd-Chiari syndrome: anastomosis of the right hepatic vein to the right atrium.

Authors:  Mircelal Kazimi; Can Karaca; Mustafa Ozsoy; Murat Ozdemir; Anil Ziya Apaydin; Sezgin Ulukaya; Murat Zeytunlu; Murat Kilic
Journal:  Liver Transpl       Date:  2009-10       Impact factor: 5.799

3.  High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome.

Authors:  Elizabeth Cruz; Nancy L Ascher; John P Roberts; Nathan M Bass; Francis Y Yao
Journal:  Clin Transplant       Date:  2005-08       Impact factor: 2.863

4.  Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report.

Authors:  Yusaku Shirai; Hitoshi Yoshiji; Saiho Ko; Masaharu Yamazaki; Yasuhide Ikenaka; Ryuichi Noguchi; Chie Morioka; Kosuke Kaji; Yosuke Aihara; Keisuke Nakanishi; Junichi Yamao; Masahisa Toyohara; Akira Mitoro; Masayoshi Sawai; Motoyuki Yoshida; Masao Fujimoto; Masahito Uemura; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  J Med Case Rep       Date:  2011-03-29

5.  Fulminant hepatic failure due to Budd Chiari syndrome.

Authors:  G I Sandle; M Layton; C O Record; W K Cowan
Journal:  Lancet       Date:  1980-05-31       Impact factor: 79.321

6.  TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.

Authors:  Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

Review 7.  Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.

Authors:  Xingshun Qi; Weirong Ren; Valerio De Stefano; Daiming Fan
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-30       Impact factor: 11.382

8.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

9.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

10.  JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.

Authors:  Hui Wang; Guixiang Sun; Peijin Zhang; Jing Zhang; Er Gui; Maoheng Zu; Enzhi Jia; Hao Xu; Lichun Xu; Jinpeng Zhang; Zhaojun Lu
Journal:  J Gastroenterol Hepatol       Date:  2014-01       Impact factor: 4.029

View more
  14 in total

1.  Abdominal pain, nausea, vomiting, and ascites in a 14-year-old girl with systemic lupus erythematosus: Answers.

Authors:  Ahmet Taner Elmas; YılmazYilmaz Tabel; Ayşe Selimoğlu; Şenay Kenç; Ramazan Kutlu
Journal:  Pediatr Nephrol       Date:  2018-09-05       Impact factor: 3.714

2.  Living Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis.

Authors:  V Gunasekaran; M S Reddy; A Rammohan; N Shanmugam; D Thiruchunapalli; R G Kanagavelu; I Kaliamoorthy; M Rela
Journal:  World J Surg       Date:  2022-09-07       Impact factor: 3.282

3.  Case of Budd-Chiari syndrome, an enigma as abdominal tuberculosis in a tubercular endemic country: A case report.

Authors:  Riya Shrestha; Saurab Karki; Bibek Timilsina; Tenzin Norphel Sherpa; Suhail Sapkota; Binaya Dhakal; Bijan Kadel
Journal:  Ann Med Surg (Lond)       Date:  2022-09-07

4.  Budd- Chiari Syndrome as an Initial Manifestation of Systemic Lupus Erythematosus.

Authors:  Jayabal Pandiaraja; Arumugam Sathyaseelan
Journal:  J Clin Diagn Res       Date:  2016-04-01

5.  Living donor liver transplantation for Budd‒Chiari syndrome with right posterior segment graft and patch plasty using the superficial femoral vein: a case report.

Authors:  Norikazu Une; Kazuaki Tokodai; Norifumi Kanai; Yoshikatsu Saitoh; Mineto Ohta; Kengo Sasaki; Koji Miyazawa; Toshiaki Kashiwadate; Atsushi Fujio; Wataru Nakanishi; Shigehito Miyagi; Michiaki Unno; Takashi Kamei
Journal:  Surg Case Rep       Date:  2021-06-04

6.  Living donor liver transplantation for Budd-Chiari syndrome: Overcoming a troublesome situation.

Authors:  Cengiz Ara; Sami Akbulut; Volkan Ince; Serdar Karakas; Adil Baskiran; Sezai Yilmaz
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

7.  Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model.

Authors:  De-Lei Cheng; Nan Zhu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Ya Liu; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

8.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

9.  Post-operative hypertension, a surrogate marker of the graft function and predictor of survival in living donor liver transplant recipients: A retrospective study.

Authors:  Manish Tandon; Anshuman Singh; Vandana Saluja; Gaurav Dubey; Vijay Kant Pandey; Chandra Kant Pandey; Sunaina Tejpal Karna; Shweta A Singh
Journal:  Indian J Anaesth       Date:  2016-07

Review 10.  An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence.

Authors:  Yu-Long Cai; Pei-Pei Song; Wei Tang; Nan-Sheng Cheng
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.